The First Clinical Study Results of RainMed's caFFR at Heart Centre in Southeast Asia were published! caFFR-guided Deferral of PCI was Safe and Comparable to Wired-based FFR Guidance!
Recently, Dr. Chandan Deepak Bhavnani from Pusat Jantung Sarawak and president of National Heart Association of Malaysia Dr. Alan Yean Yip Dr Fong's team published results of a clinical trial using coronary angiography-derived fractional flow reserve measurement system caFFR. The paper was published in Journal of Asian Pacific Society of Cardiology (JAPSC). This was the first study of its kind in Southeast Asia. Based on previous trials, this trial advances the clinical significance of caFFR value for intermediate coronary artery stenosis. The results showed that caFFR had a good agreement with wire-based FFR. The 12-month outcomes showed that caFFR-guided deferral of PCI was safe and comparable to wired-based FFR guidance.
RainMed Actively Responds to Financial Discount Interest Policy! Its Integrated Diagnosis and Treatment Plan of Vascular Diseases Promotes the Homogenization of the Diagnosis and Treatment Level Among Regions
Recently, there is a bunch of good news in the field of medical device. A few days ago, the State Council executive meeting decided to use special re-loans and financial discount interest to support the renovation of equipment in some areas, increase market demand, and increase the development momentum. At the same time, the National Health Commission also issued a notice of upgrading medical device with financial discount loans. This policy will surely stimulate the vitality of hospital procurement and promote domestic innovative medical devices to grow with vigorous market vitality
GW-ICC 2022 | RainMed Medical Successfully Held a Satellite Symposium on Computational Coronary Physiology
On October 29th, 2022, during the 33rd Great Wall International Congress of Cardiology, Asia Heart Society Congress 2022, in order to popularize the concept of coronary functional evaluation and promote the clinical application of computational coronary physiological indicators, RainMed Medical successfully held a satellite symposium of computational coronary physiology. The well-known experts in the field of cardiovascular were invited, and they discussed and prospected the latest progress of coronary functional evaluation technology, and shared the clinical experience of innovative computational physiology indicators caFFR and caIMR. It is worth noting that it is the first time that RainMed shared clinical cases of caIMR in satellite symposiums in such a national academic congress, which has attracted widespread attention and aroused heated discussion among participants.
Exhibition is Underway! RainMed's caFFR Unveiled for the First Time at the 18th Malaysian Cardiovascular Intervention Symposium
RainMed's caFFR Unveiled for the First Time at the 18th Malaysian Cardiovascular Intervention Symposium
The Vice Minister Wenpu Ma and Academician Yan Shen Visited RainMed Medical for Inspection and Guide the Development of Domestic Innovative Medical Devices
Recently, Mr. Wenpu Ma, former vice minister of the International Department of Central Committee of CPC, Former Vice Director of the 11th NPC Foreign Affairs Committee, and Professor Yan Shen, former vice chairman of China Association for Science and Technology (CAST), former deputy of National Natural Science Foundation of China and member of Chinese Academy of Sciences and the other two people visited Beijing office of RainMed Medical and fully affirmed the achievements of RainMed Medical in scientific and technological innovation. Mr. Kangjian Liu, Vice President and Secretary of the Board of Directors of RainMed and Mr. Liang Wan, Director of Government Affairs Department, accompanied them during the visit.
Good News! RainMed's caFFR System Has Been Successfully Certified by Australian TGA, Unlocking a New Area in Overseas Market!
On September 29th, 2022, RainMed Medical Co., LTD. (Stock Code: 2297.HK, hereinafter referred to as "RainMed") officially announced that its caFFR system has been successfully approved by Australian Government Department of Health Therapeutic Goods Administration(TGA), unlocking a new area in overseas market. Having got TGA’s recognition means RainMed has taken a solid step in accelerating its layout of international marketing system!
TCT 2022丨RainMed caIMR Presented at the Transcatheter Cardiovascular Therapeutics Conference, Providing a New Solution for Global Coronary Microcirculation Function Assessment
RainMed Medical, an innovative medical device enterprise from China, was invited to deliver a speech at TCT to announce its latest clinical trial data because of the original breakthrough technology of caIMR in coronary microcirculation function assessment, which showed the world China's local innovation strength.
2022 China Medical Device Outbound Conference | RainMed’s caIMR Series Won the Award of "2022 Most Innovative Outbound Medical Devices", Which Will Further Demonstrate the Infinite Charm of China’s Smart Manufacturing on the Global Stage
In September 2022, RainMed Medical was invited to participate in the 2022 China Medical Device Outbound Conference hosted by the International Health Exchange and Cooperation Center NHC PRC (IHECC) and VBDATA.CN.
2022CHC·Surgical Robot Forum: RainMed Medical Announced to Build Its Own Vascular Interventional Surgery Robot to Promote the Realization of Unmanned Operating Room
On September 1st, 2022, the "2022CHC·Citic Securities Healthcare Conference and the 11th China MedTec CEO Summit" jointly hosted by CHC Healthcare Consulting and Citic Securities, was held in Hefei, Anhui Province. The conference focused on cutting-edge research and held a special forum on surgical robots. As the strategic partner of the conference and the leader of the vascular interventional surgery robot field, RainMed Medical was invited to attend the forum. Mr. Kangjian Liu, Vice president and Secretary of the Board announced that RainMed Medical will build a platform-level vascular interventional surgery robot to promote the realization of an unmanned operating room with automated diagnosis and treatment.
RainMed Medical Satellite Symposium Has been Successfully Held During the 21st Cardiovascular Disease Academic Conference of Shanxi Medical Association
On August 27, 2022, during the 21st Cardiovascular Disease Academic Conference of Shanxi Medical Association, RainMed Medical successfully held a satellite symposium in order to popularize the clinical application of calculating coronary physiological indicators and promote precise interventional treatment of coronary heart disease. Renowned experts in the field of cardiovascular diseases were invited to discuss the latest progress of coronary functional evaluation technology and the clinical application of innovative functional indicators caFFR and caIMR.
The Kick-off Meeting of "Expert Consensus on Clinical Pathways of Coronary Artery Computational Physiology Testing Indicators in China" Led by Academician Junbo Ge and Supported by RainMed Medical Was Held in Anhui Province
On August 20, 2022, during the fourth Confucianism and Taoism International Congress of Cardiology (CTCC), the kick-off meeting of "Expert Consensus on Clinical Pathways of Coronary Artery Computational Physiology Testing Indicators in China", led by Academician Junbo Ge from Fudan University Zhongshan Hospital and supported by RainMed Medical, was held in Anhui province.
Strategic Cooperation | RainMed Medical and Angiotec Signed a Strategic Cooperation Agreement to Accelerate the Development of Integrated Solutions for Cardiovascular Operating Rooms
On August 16, 2022, RainMed Medical Co., LTD. (hereinafter referred to as "RainMed", stock code: 2297.HK) and Angiotec （Tianjin）Technology Co., Ltd. (hereinafter referred to as "Angiotec”) held a signing ceremony for strategic cooperation in Tianjin. Mr. Yunfei Huo, Chairman of the Board, Executive Director and Chief Executive Officer of RainMed and Mr. Da Zhuo, General Manager of Angiotec signed the agreement on behalf of both companies. Mr. Yonghui Lv, Executive Director and co-Chief Executive Officer of RainMed also attended the meeting.
Initial Release of caIMR's Clinical Application Potential! RainMed’s caIMR Empowered the development of clinical treatment strategies, adding strong evidence for the concept of "intervention without implantation" for STEMI patients
Recently, Professor Zhirong Wang's team from The Affiliated Hospital of Xuzhou Medical University published a paper in SCI journal titled "Computational Pressure-Fluid Dynamics Applied to Index of Microcirculatory Resistance, Predicting the Prognosis of Drug-Coated Balloons Compared With Drug-Coated Balloons Compared With Drug-Eluting Stents in STEMI Patients". The paper indicates that RainMed’s caIMR can independently predict the likelihood of cardiac death or readmission due to heart failure in STEMI patients. At the same time, caIMR confirmed that the effect of drug-coated balloon (DCB) therapy is not inferior to drug-eluting stent (DES) in the diagnosis and treatment of STEMI by accurately diagnosing the damage of coronary microcirculation. It has added strong clinical evidence for the advanced diagnosis and treatment concept of "intervention without implantation" in STEMI patients and assisted clinical development of better interventional diagnosis and treatment strategy.
18th YRICC | RainMed Medical Satellite Symposium Has Been Successfully Held
On July 22nd, 2022, during the 18th Yellow River International Cardiology Conference (YRICC 2022), RainMed Medical successfully held a satellite symposium. Renowned cardiovascular experts from all over the country had a heated discussion on research progress, clinical significance and application scenarios of caFFR and caIMR.
Warmly Celebrate the Successful Listing of RainMed on the Hong Kong Stock Exchange
On July 8, 2022, Suzhou RainMed Medical Technology Co., LTD. (02297.HK, hereinafter referred to as "RainMed Medical") was officially listed on the main board of Hong Kong Stock Exchange and held a bell ringing ceremony at 9:30 am.
ICC 2022 | RainMed Medical Successfully Held the Physiological Function Forum
On July 3rd, 2022, during the 17th Ice City Conference of Cardiology (ICC 2022), RainMed Medical successfully held the Physiological Function Forum. Renowned cardiovascular experts from all over the country had a heated discussion on research progress, clinical significance and application scenarios of caFFR and caIMR.
RainMed Medical Entered "TOP100 MEDICAL DEVICE COMPANIES"
In the sixth 2022 Future Healthcare VB100 Conference, RainMed Medical was identified as one of the "TOP100 Medical Device Companies” in China. This list is the most concerned annual list launched by VBDATA.CN and VCBeat Research (VBR) in the field of life and health among industry and capital circles. Meanwhile, it is also the first innovative medical list of unlisted enterprises in China. RainMed Medical has brought new solutions to world's problems with China's local innovation.
FIVE Amazing Features of caIMR | RainMed's Satellite Symposium at CIT was Successfully Held
At present, there is no clinical quantitative measurement product that can easily and effectively diagnose coronary microcirculation. The large-scale clinical application of caIMR--the global pioneering technology--will surely bring epoch-making significance to precise diagnosis and treatment in cardiovascular field, and provide diagnostic basis and research direction for the development of microcirculation drugs and devices. To conclude, why is caIMR so promising? We can refer to the following five reasons.
OCC 2022 | Chairman of OCC Announced the Results of Flash III Clinical Research, Confirming that caIMR Has High Diagnostic Accuracy
Recently, the 16th Oriental Congress of Cardiology was grandly held. Meanwhile, RainMed’s Satellite Meeting was also held at noon. During the conference, Junbo Ge, president of OCC Conference, chief of cardiology department of Zhongshan Hospital, Fudan University and academician of Chinese Academy of Sciences announced the results of Flash III trial. Compared with guidewire-based IMR, the online measurement accuracy of caIMR is up to 93.81%, and the offline accuracy is up to 94.69%. This exciting research result has aroused enormous experts and scholars' attention and heated discussion. In addition, the role of functional evaluation was discussed in the research progress of diagnosis and treatment of coronary heart disease and the coronary microvascular disease. Cases guided by caFFR and caIMR were shared.
New Progress! RainMed's Transducer Compatible with both caFFR and caIMR Got a New English Name
On June 7th, 2022, RainMed's transducer compatible with both caFFR and caIMR got a new English name after voting—CadiFlash, which means RainMed has made a new progress in the internationalization of caFFR and caIMR.
New Era of Precision Medicine! EuroPCR Announced Exciting Results of caIMR’s Clinical Experiments on the Coronary Microcirculation Diagnosis
Recently, at EuroPCR2022, the official annual meeting of the World-Leading Course in Interventional Cardiovascular Medicine and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), chief of cardiology department of Zhongshan Hospital, Fudan University and academician of Chinese Academy of Sciences Junbo Ge announced the excellent results of the clinical trial of Flash III supported by RainMed Medical. Data shows that compared with wire-based IMR, caIMR has high accuracy, sensitivity and specificity. This means that large-scale clinical application of caIMR will surely improve the level of diagnosis and treatment of coronary artery disease and lead precision medicine into a new era.
caFFR provides accurate coronary artery functional assessment to guide the precise interventional treatment at Wusong Hospital of Zhongshan Hospital, Fudan University.
Angiography-Derived FFR (caFFR) measurement technique was successfully developed in the Department of Cardiovascular Medicine, Wusong Hospital of Zhongshan Hospital, Fudan University. caFFR does not require invasive pressure guidewire, vasodilator and additional surgery and operations. Identical results were obtained with wire-derived FFR and caFFR.
caFFR helps a case of severe tortuous diffuse lesion with strategies and post-operational evaluation.
In the live broadcast of CCIF2020 online surgery on April 21st, 2020, Professor Li Jianping from Peking University First Hospital successfully completed a difficult operation. It is worth mentioning that when selecting treatment for patients, Professor Li Jianping referred to functional (caFFR) evaluation and imaging (OCT) evaluation and finally determined the intervention plan based on the functional data provided by caFFR.
A case of coronary artery disease with PCI treatment guided by caFFR
Source: Department of Cardiology, Fenyang Hospital, Shanxi Province, Li Yanzhen On June 4, 2020, a male patient with chest pain for more than 5 hours was admitted to the hospital. The operation was
WeChat public account
Recruitment QR Code